Publications and communications of Ingrid Struman

Shaker, B. T., Ismail, A. A., Salih, R., Hadj Kacem, H., Rahmani, M., Struman, I., & Bajou, K. (17 May 2023). The 14-Kilodalton Human Growth Hormone Fragment a Potent Inhibitor of Angiogenesis and Tumor Metastasis. International Journal of Molecular Sciences, 24 (10), 8877. doi:10.3390/ijms24108877

Guiot, J., Henket, M., Remacle, C., Cambier, M., Struman, I., Winandy, M.-L., Moermans, C., Louis, E., Malaise, M., Ribbens, C., Louis, R., & Njock, M.-S. (15 April 2023). Systematic review of overlapping microRNA patterns in COVID-19 and idiopathic pulmonary fibrosis. Respiratory Research, 24 (1), 112. doi:10.1186/s12931-023-02413-6

NJOCK, M.-S.* , O'Grady, T.* , Nivelles, O., Lion, M., Jacques, S., Cambier, M., Herkenne, S., Muller, F., Christian, A., REMACLE, C., GUIOT, J., Rahmouni, S., Dequiedt, F.* , & Struman, I.*. (June 2022). Endothelial extracellular vesicles promote tumour growth by tumour-associated macrophage reprogramming. Journal of Extracellular Vesicles, 11 (6), 12228. doi:10.1002/jev2.12228
* These authors have contributed equally to this work.

O'Grady, T.* , NJOCK, M.-S.* , Lion, M., Bruyr, J., Mariavelle, E., Galvan, B., Boeckx, A., Struman, I.* , & Dequiedt, F.*. (24 March 2022). Sorting and packaging of RNA into extracellular vesicles shape intracellular transcript levels. BMC Biology, 20 (1), 72. doi:10.1186/s12915-022-01277-4
* These authors have contributed equally to this work.

Zamberlan, M.* , Boeckx, A.* , Muller, F., Vinelli, F., Ek, O., Vianello, C., Coart, E., Shibata, K., Christian, A., Grespi, F., Giacomello, M., Struman, I., Scorrano, L.* , & Herkenne, S.*. (12 March 2022). Inhibition of the mitochondrial protein Opa1 curtails breast cancer growth. Journal of Experimental and Clinical Cancer Research, 41 (1), 95. doi:10.1186/s13046-022-02304-6
* These authors have contributed equally to this work.

Bhardwaj, A., Josse, C., VAN DAELE, D., Poulet, C., Chavez, M., Struman, I., & Van Steen, K. (2022). Deeper insights into long-term survival heterogeneity of Pancreatic Ductal Adenocarcinoma (PDAC) patients using integrative individual-and group-level transcriptome network analyses. Scientific Reports, 12 (11027). doi:10.1038/s41598-022-14592-1

Cambier, M., Henket, M., Frix, A.-N., Gofflot, S., THYS, M., Tomasetti, S., Peired, A., Struman, I., Rousseau, A.-F., Misset, B., Darcis, G., Moutschen, M., Louis, R., Njock, M.-S., Cavalier, E., & Guiot, J. (2022). Increased KL-6 levels in moderate to severe COVID-19 infection. PLoS ONE, 17 (11), 0273107. doi:10.1371/journal.pone.0273107

Fontaine, M., Herkenne, S., Ek, O., Paquot, A., Boeckx, A., Paques, C., Nivelles, O., Thiry, M., & Struman, I. (2022). Extracellular Vesicles Mediate Communication between Endothelial and Vascular Smooth Muscle Cells. International Journal of Molecular Sciences, 23 (1). doi:10.3390/ijms23010331

Roblain, Q., Louis, T., Yip, C., Baudin, L., Struman, I., Caolo, V., LAMBERT, V., Lecomte, J.* , Noël, A.* , & Heymans, S.*. (2021). Intravitreal injection of anti-miRs against miR-142-3p reduces angiogenesis and microglia activation in a mouse model of laser-induced choroidal neovascularization. Aging, 13. doi:10.18632/aging.203035
* These authors have contributed equally to this work.

GUIOT, J., Cambier, M., Boeckx, A., HENKET, M., Nivelles, O., GESTER, F., LOUIS, E., MALAISE, M., Dequiedt, F., LOUIS, R., Struman, I.* , & NJOCK, M.-S.*. (05 August 2020). Macrophage-derived exosomes attenuate fibrosis in airway epithelial cells through delivery of antifibrotic miR-142-3p. Thorax, 75 (10), 870-881. doi:10.1136/thoraxjnl-2019-214077
* These authors have contributed equally to this work.

Pérez-Boza, J., Boeckx, A., Lion, M., Dequiedt, F., & Struman, I. (2020). hnRNPA2B1 inhibits the exosomal export of miR‑503 in endothelial cells. Cellular and Molecular Life Sciences. doi:10.1007/s00018-019-03425-6

Francart, M.-E.* , Vanwynsberghe, A.* , Lambert, J., Bourcy, M., Genna, A., Ancel, J., Perez-Boza, J., Noël, A., Birembaut, P., Struman, I., Polette, M., & Gilles, C. (2020). Vimentin prevents a miR-dependent negative regulation of tissue factor mRNA during epithelial-mesenchymal transitions and facilitates early metastasis. Oncogene, 18, 3680-3692. doi:10.1038/s41388-020-1244-1
* These authors have contributed equally to this work.

Boeckx, A., Gourzonès, C., & Struman, I. (06 September 2019). The exosomal microRNA miR-503: a key modulator of resistance to chemotherapy in breast cancer cells [Poster presentation]. EDT-CANCEROLOGY ANNUAL MEETING 2019 RECENT BREAKTHROUGHS IN ANTICANCER DRUG RESISTANCE.

BONHOMME, O., ANDRE, B., GESTER, F., DE SENY, D., MOERMANS, C., Struman, I., Louis, R., MALAISE, M., & GUIOT, J. (2019). Biomarkers in systemic sclerosis-associated interstitial lung disease: review of the literature. Rheumatology (Oxford, England). doi:10.1093/rheumatology/kez230

GUIOT, J., Struman, I., Louis, E., Louis, R., Malaise, M., & Njock, M.-S. (2019). Exosomal miRNAs in Lung Diseases: From Biologic Function to Therapeutic Targets. Journal of Clinical Medicine, 8 (9). doi:10.3390/jcm8091345

Njock, M.-S., GUIOT, J., HENKET, M., Nivelles, O., Thiry, M., Dequiedt, F., Corhay, J.-L., Louis, R., & Struman, I. (2018). Sputum exosomes: promising biomarkers for idiopathic pulmonary fibrosis. Thorax. doi:10.1136/thoraxjnl-2018-211897

GUIOT, J., Struman, I., CHAVEZ, V., HENKET, M., Herzog, M., Scoubeau, K., Hardat, N., Bondue, B., Corhay, J.-L., MOERMANS, C., & Louis, R. (15 August 2017). Altered epigenetic features in circulating nucleosomes in idiopathic pulmonary fibrosis. Clinical Epigenetics, 9, 84. doi:10.1186/s13148-017-0383-x

Rambout, X., Detiffe, C., Bruyr, J., Mariavelle, E., Cherkaoui, M., Brohee, S., Demoitie, P., Lebrun, M., Soin, R., Lesage, B., Guedri, K., Beullens, M., Bollen, M., Farazi, T. A., Kettmann, R., Struman, I., Hill, D. E., Vidal, M., Kruys, V., ... Dequiedt, F. (2016). The transcription factor ERG recruits CCR4-NOT to control mRNA decay and mitotic progression. Nature Structural and Molecular Biology. doi:10.1038/nsmb.3243

Freres, P.* , Wenric, S.* , BOUKERROUCHA, M., Fasquelle, C., Thiry, J., Bovy, N., Struman, I., Geurts, P., COLLIGNON, J., SCHROEDER, H., KRIDELKA, F., LIFRANGE, E., Jossa, V., Bours, V.* , Josse, C.* , & JERUSALEM, G.*. (2015). Circulating microRNA-based screening tool for breast cancer. Oncotarget. doi:10.18632/oncotarget.6786
* These authors have contributed equally to this work.

Bovy, N., Blomme, B., Freres, P., Dederen, S., Nivelles, O., Lion, M., Carnet, O., Martial, J., Noël, A., Thiry, M., Jerusalem, G., Josse, C., Bours, V., Tabruyn, S., & Struman, I. (2015). Endothelial exosomes contribute to the antitumor response during breast cancer neoadjuvant chemotherapy via microRNA transfer. Oncotarget. doi:10.18632/oncotarget.3520

Herkenne, S., Paques, C., Nivelles, O., Lion, M., BAJOU, K., Pollenus, T., Fontaine, M., Carmeliet, P., Martial, J., Nguyen, N.-Q.-N., & Struman, I. (2015). The interaction of uPAR with VEGFR2 promotes VEGF-induced angiogenesis. Science Signaling, 8 (403), 117. doi:10.1126/scisignal.aaa2403

Halkein, J., Tabruyn, S. P., Ricke-Hoch, M., Haghikia, A., Nguyen, N.-Q.-N., Scherr, M., Castermans, K., Malvaux, L., Lambert, V., Thiry, M., Sliwa, K., Noël, A., Martial, J., Hilfiker-Kleiner, D., & Struman, I. (2013). MicroRNA-146a is a therapeutic target and biomarker for peripartum cardiomyopathy. Journal of Clinical Investigation, 123 (5), 2143-54. doi:10.1172/JCI64365

LAMBERT, V., Lecomte, J., Hansen, S., Blacher, S., Alvarez Gonzalez, M.-L., Struman, I., Sounni, N. E., Rozet, E., De Tullio, P., Foidart, J.-M., Rakic, J.-M., & Noël, A. (2013). Laser-induced choroidal neovascularization model to study age-related macular degeneration in mice. Nature Protocols, 8 (11), 2197-2211. doi:10.1038/nprot.2013.135

Tabruyn, S. P., Hansen, S., Ojeda-Fernandez, M.-L., Bovy, N., Zarrabeitia, R., Recio-Poveda, L., Bernabeu, C., Martial, J., Botella, L.-M., & Struman, I. (2013). MiR-205 is downregulated in hereditary hemorrhagic telangiectasia and impairs TGF-beta signaling pathways in endothelial cells. Angiogenesis. doi:10.1007/s10456-013-9362-9

Soares, A. R., Reverendo, M., Pereira, P. M., Nivelles, O., Pendeville, H., Bezerra, A. R., Moura, G. R., Struman, I., & Santos, M. A. S. (2012). Dre-miR-2188 Targets Nrp2a and Mediates Proper Intersegmental Vessel Development in Zebrafish Embryos. PLoS ONE, 7 (6), 39417. doi:10.1371/journal.pone.0039417

Nguyen, N.-Q.-N., Castermans, K., Berndt, S., Herkenne, S., Tabruyn, S., Blacher, S., Lion, M., Noël, A., Martial, J., & Struman, I. (07 November 2011). The Antiangiogenic 16K Prolactin Impairs Functional Tumor Neovascularization by Inhibiting Vessel Maturation. PLoS ONE, 6 (11), 27318-27318. doi:10.1371/journal.pone.0027318

Sabatel, C., Malvaux, L., Bovy, N., Deroanne, C., LAMBERT, V., Alvarez Gonzalez, M.-L., Colige, A., Rakic, J.-M., Noël, A., Martial, J., & Struman, I. (2011). MicroRNA-21 Exhibits Antiangiogenic Function by Targeting RhoB Expression in Endothelial Cells. PLoS ONE, 6 (2), 16979. doi:10.1371/journal.pone.0016979

Sabatel, C., Cornet, A., Tabruyn, S., Malvaux, L., Castermans, K., Martial, J., & Struman, I. (2010). Sprouty1, a new target of the angiostatic agent 16K prolactin, negatively regulates angiogenesis. Molecular Cancer, 9 (1), 231. doi:10.1186/1476-4598-9-231

Sliwa, K., Blauwet, L., Tibazarwa, K., Libhaber, E., Smedema, J.-P., Becker, A., McMurray, J., Yamac, H., Labidi, S., Struman, I., & Hilfiker-Kleiner, D. (2010). Evaluation of bromocriptine in the treatment of acute severe peripartum cardiomyopathy: a proof-of-concept pilot study. Circulation, 121 (13), 1465-73. doi:10.1161/CIRCULATIONAHA.109.901496

Tabruyn, S., Memet, S., Ave, P., Verhaeghe, C., Mayo, K. H., Struman, I., Martial, J., & Griffioen, A. W. (2009). NF-kappaB activation in endothelial cells is critical for the activity of angiostatic agents. Molecular Cancer Therapeutics, 8 (9), 2645-54. doi:10.1158/1535-7163.MCT-09-0383

Nguyen, N.-Q.-N., Cornet, A., Blacher, S., Tabruyn, S., Foidart, J.-M., Noël, A., Martial, J., & Struman, I. (December 2007). Inhibition of tumor growth and metastasis establishment by adenovirus-mediated gene transfer delivery of the antiangiogenic factor 16K hPRL. Molecular Therapy, 15 (12), 2094-2100. doi:10.1038/sj.mt.6300294

Piwnica, D., Touraine, P., Struman, I., Tabruyn, S., Bolbach, G., Clapp, C., Martial, J., Kelly, P. A., & Goffin, V. (October 2004). Cathepsin D processes human prolactin into multiple 16K-like N-terminal fragments: Study of their antiangiogenic properties and physiological relevance. Molecular Endocrinology, 18 (10), 2522-2542. doi:10.1210/me.2004-0200

Pan, H., Nguyen, N.-Q.-N., Yoshida, H., Bentzien, F., Shaw, L. C., Rentier-Delrue, F., Martial, J., Weiner, R., Struman, I., & Grant, M. B. (July 2004). Molecular targeting of antiangiogenic factor 16K hPRL inhibits oxygen-induced retinopathy in mice. Investigative Ophthalmology and Visual Science, 45 (7), 2413-2419. doi:10.1167/iovs.03-1001

Bentzien, F., Struman, I., Martini, J. F., Martial, J., & Weiner, R. (2001). Expression of the antiangiogenic factor 16K hPRL in human HCT116 colon cancer cells inhibits tumor growth in Rag1(-/-) mice. Cancer Research, 61 (19), 7356-62.

Martini, J. F., Piot, C., Humeau, L. M., Struman, I., Martial, J., & Weiner, R. I. (2000). The antiangiogenic factor 16K PRL induces programmed cell death in endothelial cells by caspase activation. Molecular Endocrinology, 14 (10), 1536-49. doi:10.1210/mend.14.10.0543

Lee, H., Struman, I., Clapp, C., Martial, J., & Weiner, R. I. (1998). Inhibition of urokinase activity by the antiangiogenic factor 16K prolactin: activation of plasminogen activator inhibitor 1 expression. Endocrinology, 139 (9), 3696-703. doi:10.1210/endo.139.9.6194

Goffin, V., Struman, I., Mainfroid, V., Kinet, S., & Martial, J. (23 December 1994). Evidence for a Second Receptor Binding Site on Human Prolactin. Journal of Biological Chemistry, 269 (51), 32598-606.

Goffin, V., Struman, I., Goormaghtigh, E., & Martial, J. (01 June 1993). The Addition of Nine Residues at the C-Terminus of Human Prolactin Drastically Alters Its Biological Properties. European Journal of Biochemistry, 214 (2), 483-90. doi:10.1111/j.1432-1033.1993.tb17945.x